Clinical Trials Browser

Interventional × tremelimumab × Genitourinary × Clear all

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

52 enrolled 12 charts

Prostatic Neoplasms

NCT03871036 2025-03-06

ICRA

Phase 1/2 Completed

Carcinoma, Transitional Cell

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03702179 2024-12-05

IMMUNOPRESERVE

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

NCT02819596 2024-11-04

CALYPSO

Phase 2 Completed

Carcinoma, Renal Cell

NCT03204812 2024-10-15

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

31 enrolled 12 charts

Prostatic Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03557918 2024-07-03

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Phase 2 Completed

26 enrolled 14 charts

Carcinoma, Transitional Cell

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Phase 1 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02616185 2023-11-02

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Phase 1 Terminated

91 enrolled 51 charts

Prostatic Neoplasms

NCT05120622 2023-10-31

Rideau

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms

NCT03472274 2023-04-13

DUTRENEO

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02626130 2022-07-07

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

NCT03430895 2021-12-01

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Phase 2 Completed

15 enrolled 8 charts

Urinary Bladder Neoplasms

NCT03081923 2021-05-14

APACHE

Phase 2 Terminated

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT03288532 2020-09-07

RAMPART

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT03598816 2020-08-13

PIVOT-RCC

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT04073160 2020-07-07

TRIO Bladder

Phase 1 Withdrawn

Urinary Bladder Neoplasms

NCT03234153 2020-06-17

NITIMIB

Phase 2 Terminated

Muscle-invasive Bladder Cancer

NCT00702923 2019-11-21

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Phase 1 Terminated

12 enrolled 9 charts

Prostatic Neoplasms

NCT00880854 2019-11-15

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Phase 1 Withdrawn

Urinary Bladder Neoplasms

NCT03150836 2017-10-19

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Phase 2 Withdrawn

Urinary Bladder Neoplasms

NCT00075192 2012-06-06

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Phase 1 Completed

Carcinoma, Renal Cell